Not a traditional drug phase: testing Tociliuzumab for Takayasu Arteritis
Takayasu arteritis is a chronic large-vessel vasculitis affecting the aorta and its major branches. Biologic therapies such as tumor necrosis factor inhibitors and tocilizumab are commonly used in patients with refractory or relapsing disease.
Official registry: https://clinicaltrials.gov/study/NCT07491913 · Marmara University · enrollment listed as 40
What this phase means
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Tociliuzumab, Infliximab, or Adalimumab. The registry lists allocation as na. Takayasu arteritis is a chronic large-vessel vasculitis affecting the aorta and its major branches.
They plan to enroll about 40 people at Istanbul. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Cessation of Biologic Treatment in Patients With Takayasu Arteritis in Sustained Remission
Interventions: Tociliuzumab, Infliximab, Adalimumab, Certolizumab Pegol
Primary outcome (registry wording): Proportion of Patients Maintaining Remission After Biologic Treatment Withdrawal
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Diagnosis of Takayasu arteritis according to the 2022 American College of Rheumatology/EULAR classification criteria
- Treatment with biologic therapy (TNF inhibitors or tocilizumab) for at least 3 years
- Sustained clinical, laboratory, and radiologic remission
- No change in treatment during the previous 12 months
- No glucocorticoid use within the previous 6 months
Who the registry excludes
- Presence of other active inflammatory diseases requiring biologic therapy (e.g., inflammatory bowel disease, ankylosing spondylitis)
- Inability to attend scheduled follow-up visits after treatment tapering and discontinuation
- Pregnancy or planning pregnancy during the study period
Public study contact (from the registry)
Fatma Alibaz-Oner, MD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Marmara University Pendik Training and Research Hospital — Istanbul, Turkey (Türkiye) (recruiting)
FAQ about this NCT record
Is NCT07491913 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07491913?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07491913?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary